---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-24-000036"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T16:12:57.657595+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Halozyme Q1 revenue up 21% to $196M; non-GAAP EPS $0.79, net income $76.8M

## Summary
- Revenue $195.9M (+21% YoY), driven by 21% royalty growth to $120.6M from DARZALEX and Phesgo.
- GAAP diluted EPS $0.60; non-GAAP diluted EPS $0.79, vs $0.29 and $0.47 in Q1 2023.
- Adjusted EBITDA $115.7M, up 56% from $74.3M; cash and securities $463.5M at quarter end.
- Reiterated FY 2024 guidance: revenue $915-985M, adjusted EBITDA $535-585M, non-GAAP EPS $3.55-$3.90.
- New $750M share repurchase program announced; partner milestones include $15M from BMS for nivolumab SC.

## SEC filing metadata
- accession: 0001159036-24-000036
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000036/0001159036-24-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000036/halo-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-24-000036
- JSON: https://secwatch.observer/filing/0001159036-24-000036.json
- Plain text: https://secwatch.observer/filing/0001159036-24-000036.txt

## Key facts
- Earnings Releases
  HALOZYME THERAPEUTICS, INC. reported the first quarter ended March 31, 2024 results: revenue $195.9 million, net income $76.8 million. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $195.9 million
  - Net income: $76.8 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: any general incorporation language in such filing. --- EX-99.1 (EX-99.1) --- HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.79 1 Royalty Revenue Increased 21% YOY to $121 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903624000036/0001159036-24-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.